The 44 references in paper E. KROPACHEVA S., O. ZEMLYANSKAYA A., A. DOBROVOLSKY B., E. PANCHENKO P., Е. КРОПАЧЕВА С., О. ЗЕМЛЯНСКАЯ А., А. ДОБРОВОЛЬСКИЙ Б., Е. ПАНЧЕНКО П. (2017) “ЭФФЕКТИВНОСТЬ ДЛИТЕЛЬНОЙ ТЕРАПИИ ВАРФАРИНОМ: ВЛИЯНИЕ НА ЧАСТОТУ ИШЕМИЧЕСКИХ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ И КЛИНИЧЕСКИЕ ПРЕДИКТОРЫ ИХ РАЗВИТИЯ (результаты проспективного 10-летнего наблюдения) // THE EFFICACY OF LONG-TERM WARFARIN THERAPY: THE IMPACT ON THE INCIDENCE OF ISCHEMIC CEREBROVASCULAR DISORDERS AND CLINICAL PREDICTORS OF DEVELOPING SUCH DISORDERS. (Results of a prospective 10-year follow-up study)” / spz:neicon:aterotromboz:y:2017:i:2:p:115-130

1
Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ, 2012.
(check this in PDF content)
2
ESC Guidelines for the management of atrial fibrillation 2016. DOI: http://dx.doi.org/10.1093/eurheartj/ehw210 eh w210 First published online: 27 August 2016.
(check this in PDF content)
3
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141(2 Suppl): e637S–68S. doi: 10.1378/chest.11-2306. pmid:22315274.
(check this in PDF content)
4
Feinberg WM, Seeger JF. Epidemiological features of asymptomatic cerebral infarction in patients with nonvalvular atrial fibrillation. Arch Intern Med, 1990, 150: 2340-44.
(check this in PDF content)
5
Lip GYH, Keshishian A, Kamble S et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. Thrombosis and Haemostasis, 2016, 116: 777-1002.
(check this in PDF content)
6
Arihiro S, Todo K, Koga M et al. Three-month riskbenefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study. Int J Stroke, 2016 Jul, 11(5): 565-74. doi: 10.1177/1747493016632239. Epub 2016 Feb 29.
(check this in PDF content)
7
Ba_aran Е, Dogan V, Biteker M et al. Guideline-adherent therapy for stroke prevention in atrial fibrillation in different health care settings: Results from RAMSES study. Eur J Intern Med, 2017 May, 40: 50-55. doi: 10.1016/j.ejim.2017.02.011. Epub 2017 Feb 24.
(check this in PDF content)
8
Sullivan RM, Zhang J, Zamba G et al. Relation of gender-specific risk of ischemic stroke in patients with atrial fibrillation to differences in warfarin anticoagulation control (from AFFIRM). Am J Cardiol,2012 Dec 15, 110(12): 1799-802. doi: 10.1016/j.amjcard.2012.08.014. Epub 2012 Sep 18.
(check this in PDF content)
9
Wright CB, Dong C et al. Subclinical Cerebrovascular Disease Increases the Risk of Incident Stroke and Mortality: The Northern Manhattan Study. J Am Heart Assoc,2017 Aug 28, 6(9). pii: e004069. doi:
(check this in PDF content)
10
1161/JAHA.116.004069. 10. Schwammenthal Y, Bornstein N et al. Relation of effective anticoagulation in patients with atrial fibrillation to stroke severity and survival (from the National Acute Stroke Israeli Survey. Am J Cardiol, 2010 Feb 1, 105(3): 411-6. doi: 10.1016/j.amjcard.2009.09.050. Epub 2009 Dec 22.
(check this in PDF content)
11
Connolly SJ, Ezekowitz MD, Salim Yusuf et al and the RE-LY Steering Committee and Investigators. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med, 2009, 361: 1139-1151. DOI: 10.1056/NEJMoa090556123.
(check this in PDF content)
12
Manesh RP, Mahaffey KW, Jyotsna Garg et al. and the ROCKET AF Steering Committee, for the ROCKET AF Investigators. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med,2011, 365: 883-891.
(check this in PDF content)
13
Goto S, Zhu J, Liu L et al. ARISTOTLE Investigators. Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Am Heart J, 2014 Sep, 168(3): 303-9. doi: 10.1016/j.ahj.2014.06.005.
(check this in PDF content)
14
Hart RG, Pearce LA, McBride R et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke, 1999 Jun, 30(6): 1223-1229.
(check this in PDF content)
15
Gorst-Rasmussen A, Lip GY, Larsen TB. Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care. Pharmacoepidemiol Drug Saf, 2016, 25: 1236-1244.
(check this in PDF content)
16
Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J, 2012, 33: 1500-1510.
(check this in PDF content)
17
Irie F, Kamouchi M, Hata J et al. FSR Investigators. Sex differences in short-term outcomes after acute ischemic stroke: the FUKUOKA stroke registry. Stroke, 2015 Feb, 46(2): 471-476. doi: 10.1161/STROKE AHA.114.006739. Epub 2014 Dec 30.
(check this in PDF content)
18
Hylek EM, Go A S, Chang Y et al. Anticoagulation and Risk Factors in Atrial Fibrillation. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N. Engl. J. Med., 2003, 349: 1019-1026.
(check this in PDF content)
19
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med,1994, 154(13): 1449-1457.
(check this in PDF content)
20
Abdul-Rahim AH, Fulton RL, Frank B et al. Association of improved outcome in acute ischaemic stroke patients with atrial fibrillation who receive early antithrombotic therapy: analysis from VISTA. Eur J Neurol, 2015 Jul, 22(7): 1048-1055. doi: 10.1111/ene.12577. Epub 2014 Oct 16.
(check this in PDF content)
21
Paciaroni M, Agnelli G, Falocci N et al. Early Recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: The RAF Study. Stroke, 2015 Aug, 46(8): 2175-2182. doi: 10.1161/STROKEAHA.115.008891. Epub 2015 Jun 30.
(check this in PDF content)
22
Albertsen IE, Rasmussen LH, Overvad TF et al. Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysis. Stroke, 2013 May, 44(5): 13291336. doi: 10.1161/STROKEAHA.113.000883. Epub 2013 Mar 12.
(check this in PDF content)
23
Михеева Ю.А. Пятилетнее проспективное наблюдение за больными с мерцательной аритмией, получающими терапию антагонистами витамина К. Полиморфизм генов CYP2C9, VKORC 1и безопасность терапии варфарином. Авт. канд.мед. наук. М., 2008.
(check this in PDF content)
24
Ryden L, Standl E, Bartnic M et al. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology, Eiropean Association for the Study of Diabetes. Guidelines on diabetes, prediabetes, and cardiovascular diseases: executive summary. Eur. Heart J.,2007, 28(1): 88-136.
(check this in PDF content)
25
Morris NJ, Wang SL, Stevens LK et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabeto,2001, 44(Suppl. 2): 14-21.
(check this in PDF content)
26
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J,2012, 33: 1635-7011.
(check this in PDF content)
27
Stevens PE, Levin A. Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice Guideline. Annals of Internal Medicine, 2013, 158(11): 825-830. pmid: 23732715.
(check this in PDF content)
28
Fanola CL, Mooney D, Cowan AJ et al. Incidence of severe renal dysfunction among individuals taking warfarin and implications for non-vitamin K oral anticoagulants. Am Heart J, 2017, 184: 150-155.
(check this in PDF content)
29
Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol,2011, 57: 1339-1348.
(check this in PDF content)
30
Olesen JB, Lip GY, Kamper AL et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med, 2012, 367: 625-635.
(check this in PDF content)
31
Bautista J, Bella A, Chaudhari A. Advanced chronic kidney disease in non-valvular atrial fibrillation: extending the utility of R2CHADS2 to patients with advanced renal failure. Clin Kidney J,2015 Apr, 8(2): 226-231.
(check this in PDF content)
32
Alonso A, Knopman DS, Gottesman RF et al. Correlates of Dementia and Mild Cognitive Impairment in Patients With Atrial Fibrillation: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). J Am Heart Assoc, 2017 Jul 24, 6(7): pii: e006014. doi: 10.1161/JAHA.117.006014.
(check this in PDF content)
33
Liao JN, Chao TF, Liu CJ et al. Risk and prediction of dementia in patients with atrial fibrillation—a nationwide population-based cohort study. Int J Cardiol, 2015 Nov 15, 199: 25-30. doi: 10.1016/j.ijcard.2015.06.170. Epub 2015 Jul 6.
(check this in PDF content)
34
Miyasaka Y, Barnes ME, Petersen RC et al. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a community-based cohort. Eur Heart J, 2007 Aug, 28(16): 1962-1967. Epub 2007 Apr 25.
(check this in PDF content)
35
Ball J, Carrington MJ, Stewart S, SAFETY investigators. Mild cognitive impairment in high-risk patients with chronic atrial fibrillation: a forgotten component of clinical management? Heart, 2013 Apr, 99(8): 542-547. doi: 10.1136/heartjnl-2012-303182. Epub, 2013 Jan 12.
(check this in PDF content)
36
Eggermont LH, de Boer K, Muller M et al. Cardiac disease and cognitive impairment: a systematic review. Heart, 2012 Sep, 98(18): 1334-1340. doi: 10.1136/heartjnl-2012-301682. Epub 2012 Jun 11.
(check this in PDF content)
37
Gorzelak-Pabi_ P, Zyzak S, Krewko _, Broncel M. Assessment of the mean time in the therapeutic INR range and the SAME-TT2R2 score in patients with atrial fibrillation and cognitive impairment. Pol Arch Med Wewn, 2016 Aug 9, 126(7-8): 494-501. doi: 10.20452/pamw.3475. Epub 2016 Aug 9.
(check this in PDF content)
38
Jacobs V, Woller SC, Stevens S et al. Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia. Heart Rhythm, 2014 Dec, 11(12): 2206-2213. doi: 10.1016/j.hrthm.2014.08.013. Epub 2014 Aug 9.
(check this in PDF content)
39
Palareti G, Leali N, Coccheri S et al. Hemorrhagic complications of oral anticoagulant therapy: results of a prospective multicenter study ISCOAT (Italian Study on Complications of Oral Anticoagulant Therapy). G Ital Cardiol, 1997, 27(3): 231-243.
(check this in PDF content)
40
Панченко Е., Кропачева Е. Факторы, определяющие безопасность терапии антагонистами витамина К. Врач, 2006, 3: 53-58.
(check this in PDF content)
41
Кропачева Е.С., Панченко Е.П. Безопасность длительной терапии варфарином: алгоритмы лечения и факторы, определяющие стабильность антикоагуляции. Клиницист, 2007, 4: 48-55.
(check this in PDF content)
42
Hylek EM, Evans-Molina C, Shea C et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation, 2007, 29, 115(21): 2689-2696.
(check this in PDF content)
43
Palareti G, Antonucci E, Migliaccio L et al. Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago. Intern Emerg Med, 2017 May 13. doi: 10.1007/s11739-017-1678-9. [Epub ahead of print].
(check this in PDF content)
44
Apostolakis S, Sullivan RM, Olshansky B, Lip GYH. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest, 2013 Nov, 144(5): 1555-1563. doi: 10.1378/
(check this in PDF content)